BioWorld

July 10, 2008

View Archived Issues

Portola Raises $60M in Series C Extension

Portola Pharmaceuticals Inc. raised $60 million in a Series C extension round to drive its two lead cardiovascular product candidates through Phase II clinical trials. (BioWorld Today) Read More

Study Shows Pipex's Zinc-Based Drug Improved Dry AMD

Read More

Drugs, Vaccines, Surveillance for Influenza All Get Boosts

Read More

SGX Shares Soar on Merger Giving Lilly Technology Boost

Read More

FDA Axing Approvable Letters, Adding Complete Responses

Read More

Other News To Note

Read More

Clinic Roundup

Read More